

Autophagic activity in neuronal cell death

Robert W. Button¹, Shouqing Luo^{1*}, David C. Rubinsztein^{2*}

1. Peninsula Schools of Medicine and Dentistry, Institute of Translational and Stratified Medicine, University of Plymouth, Research Way, Plymouth PL6 8BU, UK.

2. Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge CB2 0XY, UK.

* Authors for correspondence: (emails: shouqing.luo@plymouth.ac.uk and dcr1000@cam.ac.uk)

As post-mitotic cells with great energy demands, neurons depend upon the homeostatic and waste recycling functions provided by autophagy. In addition, autophagy also promotes survival during periods of harsh stress and targets aggregate-prone proteins associated with neurodegeneration for degradation. Despite this, autophagy has also been controversially described as a mechanism of programmed cell death. Instances of autophagic cell death are typically associated with elevated numbers of cytoplasmic autophagosomes, which have been assumed to lead to excessive degradation of cellular components. Due to the high activity and reliance on autophagy in neurons, these cells may be particularly susceptible to autophagic death. In this review, we summarise and assess current evidence in support of autophagic cell death in neurons, as well as how autophagy dysregulation commonly seen in neurodegeneration can contribute to neuron loss. From here, we discuss potential treatment strategies relevant to such cell death pathways.

Keywords: autophagy; autophagic cell death; programmed cell death; apoptosis; necrosis; autosis; neurodegeneration

Introduction

Autophagy is an intracellular process of self-eating, which provides homeostatic maintenance through the capture and degradation of aggregate-prone proteins and dysfunctional organelles. More specifically, autophagy encompasses three separate mechanisms- microautophagy, chaperone-mediated autophagy and macroautophagy, but only the latter will be discussed in this review, and shall be referred to as simply 'autophagy' herein^[1].

Briefly, autophagy proceeds through the capture of portions of cytoplasm containing target material inside expanding membranes, which finally enclose to form double-membrane vesicles called autophagosomes. Fully formed autophagosomes are shuttled along microtubules to lysosomes, whereupon fusion and degradation occurs^[2, 3]. This removal and recycling serves as an emergency energy supply during starvation, but autophagy has also been linked to a diverse range of other protective roles^[4-7]. These include the capture of invading pathogens^[8], context-dependent tumour suppressive and tumorigenic qualities^[9-12], and the removal of toxic aggregate-prone proteins often linked to neurodegeneration^[13-15]. From these findings, interest in autophagy research has surged over the past decade or so^[16].

Despite these pro-survival roles, autophagy has also been implicated as a mechanism of programmed cell death (PCD)^[17-19]. Numerous studies have reported instances of dying cells displaying accumulated autophagosomes, which engulf large portions of the cell's cytoplasm and which have been presumed to lead to excessive destruction of vital components^[20, 21]. However, this notion of 'autophagic cell death' (ACD) has met with some scepticism, with critics arguing that these accumulations of autophagosomes may represent a failed rescue response to a lethal stress, as opposed to a direct lethal mechanism in its own right^[22-24].

Neurons have high energy demands, and as post-mitotic cells, quality control and homeostasis maintenance is vital^[25]. From these traits, one would assume neurons to rely heavily on autophagy. Yet, these cells typically display very few autophagosomes, suggesting little autophagic activity. However, impairing lysosomal function leads to the accumulation of autophagosomes, revealing that autophagy is highly efficient in neurons, with a quick progression from vesicle formation to

degradation^[26, 27]. Due to this high autophagic flux, it is possible that neurons are particularly sensitive to ACD. As pathologies like neurodegeneration are associated with a progressive loss of neurons, an appreciation of the diverse mechanisms of death in these cells may aid the design of future protective and preventative treatments for disease. In this review, after briefly covering the autophagy machinery, we will compare the seemingly paradoxical roles autophagy plays in both promoting cell survival and death in neurons. From there, we will address the implications these have for our understanding of ACD, as well as potential applications for neuron therapy.

Regulation of the Autophagy Machinery

The autophagy machinery is highly conserved. The AuTophagy-related (Atg) genes were first observed in yeast^[28, 29], but many of the 30+ members of this group have mammalian homologues^[30]. The different Atg genes regulate each stage of autophagosome formation - from initiation of the process, to the nucleation of the target membrane, and finally its subsequent elongation and fusion, forming the complete vesicle^[31]. Various origins of the membrane have been suggested; with sites including the endoplasmic reticulum (ER)^[32, 33], plasma membrane^[34-36], mitochondrial membrane^[37] and Golgi apparatus^[38] all receiving support as sources.

Under normal conditions, autophagy proceeds at a relatively low basal rate. Multiple regulators of autophagy have been identified, but in mammals the best characterised is the mammalian Target of Rapamycin (mTOR), which negates the initiation of autophagosome formation. However, upon certain stimuli such as starvation, mTOR is inactivated, allowing autophagy to proceed. The initial stages of the process are mediated by the un-coordinated 51-like kinase 1 (ULK1) complex, which activates the downstream Phosphatidylinositol 3-Kinase (PI3K) Class III complex^[39]. Vps34, the only mammalian Class III PI3K, catalyses PI(3)P generation, allowing for recruitment of additional facilitators of autophagosome nucleation. Recently, PI(5)P has been shown to be able to substitute for PI(3)P in this regard, and this lipid is particularly important in responses to glucose starvation^[40]. Membrane elongation is completed through the action of two ubiquitin-like conjugation processes: 1) ATG12-5; 2) LC3-phosphatidylethanolamine (PE)^[41-43]. Although the ATG12-5-16L1 complex

dissociates from completed vesicles, the LC3-PE conjugate (LC3-II) remains, making it a commonly-used marker of autophagosomes^[44]. At the end of the process, autophagosomes are shuttled to lysosomes and autophagosome-lysosome fusion occurs (Fig 1). Lysosomal enzymes like cathepsins degrade the vesicles and their cargo, and permeases release amino acids for recycling^[45]. The successful progression from autophagosome formation to degradation is referred to as 'autophagy flux'.

Autophagy in neuronal survival

Perhaps the clearest demonstration of the importance of autophagy in survival is that complete knockout of several of the Atg genes (such as Atg3, 5, 7, 9 and 16L1) results in neonatal lethality in mice^[30]. Neuron-specific Atg gene knockouts specifically reveal that basal rates of autophagy are required for normal neuronal survival^[46, 47]. Autophagy is utilised as a protective mechanism in response to numerous stresses. As well as during harsh environmental cues such as starvation^[48, 49] or hypoxia^[50], autophagy action can also promote survival through the clearance of faulty intracellular material. For instance, the specialised subdivision of autophagy that targets mitochondria, mitophagy, serves as a form of quality control for these organelles. Defective mitochondria are targeted by a machinery including PTEN-induced kinase 1 (PINK1) and the ubiquitin ligase Parkin, which ubiquitinates proteins on their outer membrane, allowing for their selective engulfment in autophagosomes. The removal of damaged mitochondria limits the risk of further damage from reactive oxygen species (ROS) generation^[51-53]. In the event of ROS production, autophagy is triggered by upstream activators like AMPK, or by increased activity of ATG proteins, again affording protection to cells^[53]. In some circumstances, autophagy suppresses apoptosis and necrosis^[54-57]. Given these roles, it is of little surprise that autophagy has emerged as one of the central targets in anti-ageing studies. Regimens that enhance the process have led to reductions in pathologies that manifest with age across several models^[58].

One of the branches of age-related disease that autophagy has been shown to influence is neurodegeneration. A common feature shared across these pathologies is the progressive accumulation of toxic aggregate-prone proteins. The identity of the

aggregates varies between diseases: Alzheimer's disease (AD) features amyloid- β (A β) plaques and intracellular Neurofibrillary Tangles (NFTs) containing Tau aggregates^[59, 60]; Parkinson's disease (PD) is characterised by Lewy body inclusions that have α -synuclein as a major constituent^[61, 62]; and Huntington's disease (HD) is the result of polyglutamine expansions of the huntingtin (Htt) protein^[13, 63]. As neurons are post-mitotic, 'in-house' modes of waste clearance are imperative to prevent the formation of these build-ups^[25]. Autophagy seems vital in this regard, as the narrow entry to the proteasome precludes it handling oligomeric assemblies^[15]. Therefore, autophagy dysfunction is likely a major contributor to the onset of neurodegeneration. Indeed, autophagic activity has been suggested to decrease with age in human tissues, including the brain^[15, 64, 65]. In some cases, degenerating neurons show accumulations of non-degraded autophagosomes in addition to the aggregates, implicating a failure of the lysosomal clearance stage in these diseases^[66-68]. An interesting exception is in the case of HD, where mutant Htt appears to reduce the recognition and capture of certain cargoes, as revealed by the recently discovered roles that the protein plays in autophagosome-substrate interactions^[69, 70].

Consistent with these data, knockout of the autophagy regulators Atg5 or Atg7 in the mouse CNS results in pathologies comparable to the effects of neurodegeneration, including the presence of protein aggregates coupled with neuronal damage and loss^[46, 47]. Beclin-1 (mammalian Atg6 homologue) activity decreases in ageing and neurodegenerative brains, and similarly, its loss enhances aggregate formation in models of AD, PD and HD^[64, 71]. Strategies of beclin-1 overexpression complement these findings, with enhanced clearance of toxins and reduced neuronal damage^[66, 72]. Mutations commonly associated with neurodegenerative pathologies have also been shown to affect autophagy. As examples, mutated Presenilin-1 in AD alters the acidification of lysosomes, causing a blockage to autophagosome degradation^[73]. The AD PICALM locus is a well validated hit from genome-wide association studies and loss of this protein impairs autophagy and tau clearance and toxicity^[74]. In PD, defects in Parkin and PINK-1 result in insufficient labelling of damaged mitochondria for mitophagy, increasing the risk of ROS generation and further neuron damage^[59]. Furthermore, α -synuclein accumulation which characterises this disease impairs

autophagosome formation^[75, 76], and the VPS35 D620N PD mutation has a similar impact on the pathway, which impairs autophagy substrate clearance^[77].

Autophagy in cell death

Are increases in autophagy activity always beneficial for neuronal health? The concept of ACD has persisted from the early days of autophagy research, representing Class II death in the recently abandoned morphological classifications of PCD, alongside apoptosis (Class I), and necrosis (Class III)^[23, 78]. Cells undergoing ACD are characterised by enhanced numbers of autophagosomes, resulting in extensive cytoplasmic vacuolisation^[17, 20]. This has largely been attributed to increases in autophagosome synthesis and flux, causing excessive degradation of important cell components^[78]. However, this concept has courted controversy across the literature, with some groups proposing these increases in autophagic vacuoles are representative of roles more in keeping with autophagy as a pro-survival system^[22, 24]. Suggestions include autophagy up-regulation as a failing salvage effort against lethal stresses, or a clearance system of dying cells, rather than a direct route of cell death in and of itself. To try and provide more clarity on this issue, various guidelines have been suggested which themselves have attracted criticism for being overly stringent^[19, 23]. It has been proposed that for an instance of cell death to be truly mediated by autophagy, then autophagy ablation by pharmacological or genetic inhibitors should provide some protection from lethality. In addition, suppression of apoptotic or necrotic processes should provide no such alleviation. Several cases of ACD have been strongly supported, such as large scale-clearance during development^[79-81], and the actions of some chemotherapeutic treatments, at least *in vitro*^[21, 82-85]. While a number of studies have supported the concept of autophagic cell death, for instance by showing that the death is attenuated by loss of autophagic genes^[21, 79, 85, 86], the interpretations of such studies are not always straightforward. It is possible that one requires some autophagy to enable execution of cell death after certain insults, and such experimental paradigms using autophagy null states certainly support the concept that autophagy may be permissive in these scenarios. However, in order to test if the increased autophagy associated with certain forms of cell death is causal, one needs to ideally manipulate

autophagy back to normality and not to the null state. As this type of manipulation is very challenging, most studies have not excluded the possibility that the increased autophagy they observed is not causing the cell death but rather that some autophagy is required to execute cell death in a manner analogous to ATP being required for apoptosis. The extent of autophagy modulation of cell death may depend on cellular contexts and on the duration and strength of autophagy induction. Berry and Baehrecke^[79] initially observed that both autophagy and caspase activity are required for the cell death in salivary glands during *Drosophila* development, and autophagy selectively degrades the caspase inhibitor dBruce to induce *Drosophila* ovary cell death^[87]. These studies suggest that multiple possible mechanisms may be involved in ACD. In mammalian cells, the role of cellular contexts in ACD remains more elusive, whilst autophagy-relevant proteins such as beclin-1, Atg7 or DRAM were reported to play a role in cell death in a variety of tumour cell lines^[88].

ACD in excitotoxic and ischaemic neuron stress

Some of the strongest support for ACD as a pathological process has been found from conditions of excitotoxicity and hypoxia-ischaemia, stresses that may result from traumatic injuries or stroke^[89, 90]. Both conditions are potent inducers of autophagy, a response presumably associated with damage limitation and survival promotion^[91]. Some have reported that pharmacological induction of autophagy with rapamycin reduces apoptotic and necrotic death during hypoxia, whilst inhibition with 3-methyladenine (3-MA) and wortmannin enhance this loss^[50, 91, 92]. Contrary to this, multiple groups have reported that instead this increase in autophagy can contribute to lethality. Using the glutamate receptor activator kainate as a model of excitotoxicity results in death in rat cortical neurons which is largely independent of apoptotic caspase activation. However, this cell death is reduced by repression of autophagosome formation using the PI3K inhibitor 3-MA, or via genetic knockdown of Atg7 and beclin-1^[93]. These observations have been supported in other excitotoxic models^[94, 95]. Similar approaches during hypoxia-ischaemia have also aided in alleviating neuron loss both *in vitro* and *in vivo*. The administration of 3-MA has proven neuroprotective in multiple rodent hypoxia-ischaemia models^[96, 97], although it

is worth bearing in mind that this agent inhibits multiple PI3 kinases and thus has many autophagy-independent effects. Interestingly, Atg7 loss in pyramidal neurons appears to suppress both caspase-dependent and -independent death, suggesting that apoptosis and ACD may both occur in neurons under hypoxia, with autophagy serving as a positive mediator of both processes^[94]. The distinctive morphological changes and increases in autophagic vesicles following hypoxia of rat hippocampal neurons has even aided in the coining of a new subtype of ACD, autosis. Autosis has been characterised by an increase in both autophagosomes and autolysosomes, and displays other unique morphological characteristics, such as a mild extent of chromatin condensation and focal swelling of the perinuclear space^[86, 98]. Notably, autotic death shows an independence from apoptosis and necroptosis, instead requiring the activity of the Na⁺, K⁺-ATPase. This pump can be blocked with cardiac glycosides. Neriifolin belongs to this class of compounds, and reduces cerebral infarct size in multiple rodent ischaemic models^[99]. Importantly, these improvements in neuron survival are coupled with a decline in the number of autophagic vesicles, as well as the absence of other autotic features^[86]. Therefore, autosis seems to be a distinct form of canonical ACD that occurs in neurons. The dependence of this phenomenon on the Na⁺, K⁺-ATPase may be relevant for the treatment of hypoxia-ischaemia, as many cardiac glycosides have well characterised safety profiles and are widely used in clinical medicine^[99].

So, how can we explain these dramatically opposing results of autophagy activation on cell death susceptibility? One possibility is that the extent of autophagy induction dictates the outcome. Physiological levels likely still serve a protective role, and provide an energy source and relief from oxidative stress. However, over-activation may lead to destruction of cellular components, as well as exerting additional strains on the neuron through continued autophagosome formation^[89, 100] (Fig 2). This form of ACD by excessive autophagosome stimulation has also been implicated in the neurotoxicity caused by drugs such as MDMA^[101]. The involvement of other forms of PCD appears to vary under ischaemic stresses, with both caspase-dependent and -independent cases documented^[94, 97]. Whilst neuron type seems an unlikely determinant of which scenario takes place (as both have been observed in the same population of pyramidal neurons^[94]), the neuronal region or nature of the stress may shape the outcome^[89]. It is important to consider that to date there is no evidence

that specific activation of autophagy induces cell death, and thus it is possible that other signalling pathways induced by different neuronal stressors may determine the impact of autophagic activity on cell survival. It has even been postulated that in certain circumstances, autophagy may promote apoptosis as a form of damage limitation against inflammatory necrosis^[91].

Autophagy-lysosome dysfunction in neurodegenerative disease

Rather than over-activation of autophagosome synthesis, the combination of autophagosome and aggregate accumulations seen in neurodegenerative cells are frequently the result of impaired lysosome degradation^[63, 102]. Therefore, in such instances it seems unlikely that ACD is occurring via excessive degradation of cellular components, as there will be impaired autophagic flux. However, these accumulations may still have detrimental effects on cell survival. Without a means of waste removal, the hallmark toxic aggregates associated with conditions like AD, PD and HD can accumulate^[59]. Other important homeostatic processes, such as faulty organelle removal, will not be fulfilled either in these conditions, which may exacerbate damage. Neurotoxins like rotenone and MPTP mimic PD pathology by inhibiting complex I of the mitochondrial electron transport chain and causing ROS generation^[103-105]. Defective mitochondria may disrupt the microtubule-dependent trafficking of autophagosomes to lysosomes further, decreasing clearance of aggregates and ROS even more^[106]. These conditions also favour mitochondrial release of cytochrome c to the cytosol, promoting cell death by apoptosis^[107]. Elevated ROS have a negative impact on lysosomes: decreasing both number and their membrane integrity. Lysosomal membrane permeabilisation (LMP) can lead to leakage of proteases like cathepsins with damaging consequences^[104, 105]. Whilst these events can hardly be classified as a bona fide case of ACD, it still highlights how impairment of the system can lead to neuron death (Fig 3). Autophagy-lysosome dysfunction associated death is likely to be of particular relevance to conditions like AD and PD, which commonly display defective autophagy flux^[15, 59, 104].

In such cases, efforts should focus on salvaging lysosomal function and boosting autophagy flux. Pharmacological autophagy inducers have been trialled across a variety of animal models, and can aid the removal of aggregates associated with AD,

PD and HD^[59, 108, 109]. In some cases, these treatments provide a degree of cognitive restoration^[71, 110]. Notably, a number of these therapies have been achieved with approved drugs, such as rapamycins^[71, 111-114], rilmenidine and spermidine^[110, 115].

A variety of strategies aimed at a number of targets have adopted this concept, with some encouraging findings. Agents like the small molecule GTM-1 and natural product Arctigenin both enhance autophagic clearance, and are associated with reductions in toxic aggregates and improved cognition in AD mouse models^[116, 117]. Boosting cathepsin activity also provides similar benefits, although the incidence of lysosomal membrane permeabilisation in some disease states may make this mechanism unfeasible^[118]. Glucosylceramide (GlcCer) has been associated with reductions in lysosomal activity, and inhibitors of GlcCer appear to provide the desired restorative effects for the organelles and improve PD pathology^[119, 120]. Niemann-Pick Type C (NPC) is another neurodegenerative disease that bears similar pathology to AD^[121]. In NPC mice, enhancing degradation aids neuron survival^[122]. An exciting candidate that has emerged in recent years is the Transcription Factor EB (TFEB). TFEB is a positive regulator of a number of lysosomal and autophagy related genes, with its expression associated with enhanced lysosome biogenesis and substrate clearance^[123]. As brains of neurodegenerative mice models have been reported to show reductions in TFEB, the effects of elevating its expression have been investigated^[25, 67]. Importantly, increased TFEB aids in the degradation of misfolded Tau^[124], α -synuclein^[67] and mutant Htt^[25] both *in vitro* and *in vivo*. There has been less clear support for A β plaque removal^[124]. Pharmacological autophagy inducers like rapamycin and trehalose also activate TFEB, and aid in the clearance of protein aggregates in neurodegenerative mouse models, as well as reduce the damage associated with neurotoxins like rotenone and MPTP^[67, 104, 105]. Table 1 summarises selected pharmacological agents/strategies used for autophagy flux restoration in neurodegenerative models.

Concluding Remarks

The role of autophagy in neuronal survival appears complex. Whilst the homeostatic functions of autophagy seem vital for survival through protection against stress and the removal of toxins, imbalances in the pathway can promote lethality. Interestingly,

it appears that both over-activation and inactivation of autophagy can lead to neuronal death. Support for ACD by autophagy over-activation has come from observations made during periods of harsh stress like excitotoxicity and hypoxia. In these situations, it is possible autophagy acts as an out-of-control protective response, and induces death by excess capture and destruction of intracellular components. Genetic ablation of the autophagy machinery can alleviate this phenomenon. However, it is important to consider that the experimental paradigms that led to the conclusions of autophagic cell death generally use autophagy null states or chemical inhibitors like 3-MA or wortmannin which have multiple autophagy-independent effects. Thus, autophagy may be permissive for certain forms of cell death, but may not be sufficient – we are not aware of any data showing that “specific” autophagy hyper-activation by overexpressing a complete ATG gene induces cell death. Lysosome dysfunction can also lead to cellular aberrant autophagosome accumulation through a block of their degradation, and is associated with neurodegenerative pathologies. In such cases there is reduced autophagic flux and the failure to successfully clear intracellular protein aggregates and ROS means the toxins can propagate unchecked and cause further damage, ultimately leading to cellular demise. These differing mechanisms will influence treatment strategies. Whilst autophagy inhibitors may improve survival in ACD by autophagosome biogenesis over-activation, their application is likely of little use in lysosomal dysfunction. For the latter instance, therapies should instead focus on restoration of lysosomal function and autophagy flux. Therefore, it is clear that targeting autophagy for cell death prevention is not a case of ‘one size fits all’, and rather, careful consideration is needed before selecting a treatment strategy.

ACKNOWLEDGEMENTS

DCR is funded by a Wellcome Trust Principal Research Fellowship. This work is supported by Plymouth University and Northcott Medical Foundation.

REFERENCES

1. Feng, Y., et al., *The machinery of macroautophagy*. Cell Res, 2014. **24**(1): p. 24-41.
2. Shibutani, S.T. and T. Yoshimori, *A current perspective of autophagosome biogenesis*. Cell Res, 2014. **24**(1): p. 58-68.
3. Yang, Z. and D.J. Klionsky, *Eaten alive: a history of macroautophagy*. Nat Cell Biol, 2010. **12**(9): p. 814-22.
4. Rabinowitz, J.D. and E. White, *Autophagy and metabolism*. Science, 2010. **330**(6009): p. 1344-8.
5. Russell, R.C., H.X. Yuan, and K.L. Guan, *Autophagy regulation by nutrient signaling*. Cell Res, 2014. **24**(1): p. 42-57.
6. Rubinsztein, D.C., P. Codogno, and B. Levine, *Autophagy modulation as a potential therapeutic target for diverse diseases*. Nat Rev Drug Discov, 2012. **11**(9): p. 709-30.
7. Button, R.W., et al., *Artesunate induces necrotic cell death in schwannoma cells*. Cell Death Dis, 2014. **5**: p. e1466.
8. Levine, B., N. Mizushima, and H.W. Virgin, *Autophagy in immunity and inflammation*. Nature, 2011. **469**(7330): p. 323-35.
9. Mathew, R., et al., *Autophagy suppresses tumorigenesis through elimination of p62*. Cell, 2009. **137**(6): p. 1062-75.
10. Cianfanelli, V., et al., *AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation*. Nat Cell Biol, 2015. **17**(1): p. 20-30.
11. Ding, W.X., et al., *Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy*. Mol Cancer Ther, 2009. **8**(7): p. 2036-45.
12. Kimmelman, A.C., *The dynamic nature of autophagy in cancer*. Genes Dev, 2011. **25**(19): p. 1999-2010.
13. Ravikumar, B., R. Duden, and D.C. Rubinsztein, *Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy*. Hum Mol Genet, 2002. **11**(9): p. 1107-17.
14. Sarkar, S., et al., *Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies*. Cell Death Differ, 2009. **16**(1): p. 46-56.
15. Tan, C.C., et al., *Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy*. Neurobiol Aging, 2014. **35**(5): p. 941-57.
16. Ohsumi, Y., *Historical landmarks of autophagy research*. Cell Res, 2014. **24**(1): p. 9-23.
17. Schweichel, J.U. and H.J. Merker, *The morphology of various types of cell death in prenatal tissues*. Teratology, 1973. **7**(3): p. 253-66.
18. Kourtis, N. and N. Tavernarakis, *Autophagy and cell death in model organisms*. Cell Death Differ, 2009. **16**(1): p. 21-30.
19. Clarke, P.G. and J. Puyal, *Autophagic cell death exists*. Autophagy, 2012. **8**(6): p. 867-9.
20. Shi, R., et al., *Excessive autophagy contributes to neuron death in cerebral ischemia*. CNS Neurosci Ther, 2012. **18**(3): p. 250-60.
21. Shimizu, S., et al., *Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes*. Nat Cell Biol, 2004. **6**(12): p. 1221-8.
22. Kroemer, G. and B. Levine, *Autophagic cell death: the story of a misnomer*. Nat Rev Mol Cell Biol, 2008. **9**(12): p. 1004-10.
23. Shen, S., O. Kepp, and G. Kroemer, *The end of autophagic cell death?* Autophagy, 2012. **8**(1): p. 1-3.
24. Shen, H.M. and P. Codogno, *Autophagic cell death: Loch Ness monster or endangered species?* Autophagy, 2011. **7**(5): p. 457-65.

25. Tsunemi, T., et al., *PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function*. Sci Transl Med, 2012. **4**(142): p. 142ra97.
26. Boland, B., et al., *Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease*. J Neurosci, 2008. **28**(27): p. 6926-37.
27. Nikolettou, V., M. Papandreou, and N. Tavernarakis, *Autophagy in the physiology and pathology of the central nervous system*. Cell Death Differ, 2014.
28. Tsukada, M. and Y. Ohsumi, *Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae*. FEBS Lett, 1993. **333**(1-2): p. 169-74.
29. Thumm, M., et al., *Isolation of autophagocytosis mutants of Saccharomyces cerevisiae*. FEBS Lett, 1994. **349**(2): p. 275-80.
30. Mizushima, N. and B. Levine, *Autophagy in mammalian development and differentiation*. Nat Cell Biol, 2010. **12**(9): p. 823-30.
31. Yang, Z. and D.J. Klionsky, *An overview of the molecular mechanism of autophagy*. Curr Top Microbiol Immunol, 2009. **335**: p. 1-32.
32. Axe, E.L., et al., *Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum*. J Cell Biol, 2008. **182**(4): p. 685-701.
33. Hayashi-Nishino, M., et al., *A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation*. Nat Cell Biol, 2009. **11**(12): p. 1433-7.
34. Ravikumar, B., et al., *Plasma membrane contributes to the formation of pre-autophagosomal structures*. Nat Cell Biol, 2010. **12**(8): p. 747-57.
35. Ravikumar, B., K. Moreau, and D.C. Rubinsztein, *Plasma membrane helps autophagosomes grow*. Autophagy, 2010. **6**(8): p. 1184-6.
36. Puri, C., et al., *Diverse autophagosome membrane sources coalesce in recycling endosomes*. Cell, 2013. **154**(6): p. 1285-99.
37. Hailey, D.W., et al., *Mitochondria supply membranes for autophagosome biogenesis during starvation*. Cell, 2010. **141**(4): p. 656-67.
38. van der Vaart, A., J. Griffith, and F. Reggiori, *Exit from the Golgi is required for the expansion of the autophagosomal phagophore in yeast Saccharomyces cerevisiae*. Mol Biol Cell, 2010. **21**(13): p. 2270-84.
39. Mizushima, N., *The role of the Atg1/ULK1 complex in autophagy regulation*. Curr Opin Cell Biol, 2010. **22**(2): p. 132-9.
40. Vicinanza, M., et al., *PI(5)P regulates autophagosome biogenesis*. Mol Cell, 2015. **57**(2): p. 219-34.
41. Hanada, T., et al., *The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy*. J Biol Chem, 2007. **282**(52): p. 37298-302.
42. Klionsky, D.J. and B.A. Schulman, *Dynamic regulation of macroautophagy by distinctive ubiquitin-like proteins*. Nat Struct Mol Biol, 2014. **21**(4): p. 336-45.
43. Satoo, K., et al., *The structure of Atg4B-LC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy*. Embo j, 2009. **28**(9): p. 1341-50.
44. Fujita, N., et al., *The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy*. Mol Biol Cell, 2008. **19**(5): p. 2092-100.
45. Shen, H.M. and N. Mizushima, *At the end of the autophagic road: an emerging understanding of lysosomal functions in autophagy*. Trends Biochem Sci, 2014. **39**(2): p. 61-71.
46. Hara, T., et al., *Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice*. Nature, 2006. **441**(7095): p. 885-9.
47. Komatsu, M., et al., *Loss of autophagy in the central nervous system causes neurodegeneration in mice*. Nature, 2006. **441**(7095): p. 880-4.

48. Mizushima, N., et al., *In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker*. Mol Biol Cell, 2004. **15**(3): p. 1101-11.
49. Kanamori, H., et al., *Functional significance and morphological characterization of starvation-induced autophagy in the adult heart*. Am J Pathol, 2009. **174**(5): p. 1705-14.
50. Carloni, S., et al., *Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia*. Autophagy, 2010. **6**(3): p. 366-77.
51. Youle, R.J. and D.P. Narendra, *Mechanisms of mitophagy*. Nat Rev Mol Cell Biol, 2011. **12**(1): p. 9-14.
52. Matsuda, N., et al., *PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy*. J Cell Biol, 2010. **189**(2): p. 211-21.
53. Poillet-Perez, L., et al., *Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy*. Redox Biol, 2015. **4c**: p. 184-192.
54. Boya, P., et al., *Inhibition of macroautophagy triggers apoptosis*. Mol Cell Biol, 2005. **25**(3): p. 1025-40.
55. Luo, S. and D.C. Rubinsztein, *Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL*. Cell Death Differ, 2010. **17**(2): p. 268-77.
56. Farkas, T., M. Daugaard, and M. Jaattela, *Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy*. J Biol Chem, 2011. **286**(45): p. 38904-12.
57. Luo, S., et al., *Bim inhibits autophagy by recruiting Beclin 1 to microtubules*. Mol Cell, 2012. **47**(3): p. 359-70.
58. de Cabo, R., et al., *The search for antiaging interventions: from elixirs to fasting regimens*. Cell, 2014. **157**(7): p. 1515-26.
59. Menzies, F.M., K. Moreau, and D.C. Rubinsztein, *Protein misfolding disorders and macroautophagy*. Curr Opin Cell Biol, 2011. **23**(2): p. 190-7.
60. Cheung, Y.T., et al., *Temporal relationship of autophagy and apoptosis in neurons challenged by low molecular weight beta-amyloid peptide*. J Cell Mol Med, 2011. **15**(2): p. 244-57.
61. Friedman, L.G., et al., *Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain*. J Neurosci, 2012. **32**(22): p. 7585-93.
62. Recasens, A. and B. Dehay, *Alpha-synuclein spreading in Parkinson's disease*. Front Neuroanat, 2014. **8**: p. 159.
63. Martin, D.D., et al., *Autophagy in Huntington disease and huntingtin in autophagy*. Trends Neurosci, 2015. **38**(1): p. 26-35.
64. Shibata, M., et al., *Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1*. J Biol Chem, 2006. **281**(20): p. 14474-85.
65. Michiorri, S., et al., *The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy*. Cell Death Differ, 2010. **17**(6): p. 962-74.
66. Spencer, B., et al., *Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases*. J Neurosci, 2009. **29**(43): p. 13578-88.
67. Decressac, M., et al., *TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity*. Proc Natl Acad Sci U S A, 2013. **110**(19): p. E1817-26.
68. Cortes, C.J., et al., *Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA*. Nat Neurosci, 2014. **17**(9): p. 1180-9.
69. Martinez-Vicente, M., et al., *Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease*. Nat Neurosci, 2010. **13**(5): p. 567-76.
70. Ochaba, J., et al., *Potential function for the Huntingtin protein as a scaffold for selective autophagy*. Proc Natl Acad Sci U S A, 2014. **111**(47): p. 16889-94.

71. Spilman, P., et al., *Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease*. PLoS One, 2010. **5**(4): p. e9979.
72. Pickford, F., et al., *The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice*. J Clin Invest, 2008. **118**(6): p. 2190-9.
73. Lee, J.H., et al., *Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations*. Cell, 2010. **141**(7): p. 1146-58.
74. Moreau, K., et al., *PICALM modulates autophagy activity and tau accumulation*. Nat Commun, 2014. **5**: p. 4998.
75. Winslow, A.R., et al., *alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease*. J Cell Biol, 2010. **190**(6): p. 1023-37.
76. Corrochano, S., et al., *alpha-Synuclein levels modulate Huntington's disease in mice*. Hum Mol Genet, 2012. **21**(3): p. 485-94.
77. Zavodszky, E., et al., *Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy*. Nat Commun, 2014. **5**: p. 3828.
78. Galluzzi, L., et al., *Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012*. Cell Death Differ, 2012. **19**(1): p. 107-20.
79. Berry, D.L. and E.H. Baehrecke, *Growth arrest and autophagy are required for salivary gland cell degradation in Drosophila*. Cell, 2007. **131**(6): p. 1137-48.
80. Denton, D., et al., *Autophagy, not apoptosis, is essential for midgut cell death in Drosophila*. Curr Biol, 2009. **19**(20): p. 1741-6.
81. Chu, C.T., *Autophagic stress in neuronal injury and disease*. J Neuropathol Exp Neurol, 2006. **65**(5): p. 423-32.
82. Grander, D., et al., *Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies*. Autophagy, 2009. **5**(8): p. 1198-200.
83. Laane, E., et al., *Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy*. Cell Death Differ, 2009. **16**(7): p. 1018-29.
84. Elgendy, M., et al., *Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival*. Mol Cell, 2011. **42**(1): p. 23-35.
85. Sharma, K., et al., *Cytotoxic autophagy in cancer therapy*. Int J Mol Sci, 2014. **15**(6): p. 10034-51.
86. Liu, Y., et al., *Autosis is a Na⁺,K⁺-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia*. Proc Natl Acad Sci U S A, 2013. **110**(51): p. 20364-71.
87. Nezis, I.P., et al., *Autophagic degradation of dBruce controls DNA fragmentation in nurse cells during late Drosophila melanogaster oogenesis*. J Cell Biol, 2010. **190**(4): p. 523-31.
88. Das, G., B.V. Shrivage, and E.H. Baehrecke, *Regulation and function of autophagy during cell survival and cell death*. Cold Spring Harb Perspect Biol, 2012. **4**(6).
89. Chen, W., et al., *Autophagy: a double-edged sword for neuronal survival after cerebral ischemia*. Neural Regen Res, 2014. **9**(12): p. 1210-6.
90. Xu, F., J.H. Gu, and Z.H. Qin, *Neuronal autophagy in cerebral ischemia*. Neurosci Bull, 2012. **28**(5): p. 658-66.
91. Balduini, W., S. Carloni, and G. Buonocore, *Autophagy in hypoxia-ischemia induced brain injury: evidence and speculations*. Autophagy, 2009. **5**(2): p. 221-3.
92. Wang, P., et al., *Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia*. Autophagy, 2012. **8**(1): p. 77-87.
93. Ginet, V., et al., *Involvement of autophagy in hypoxic-excitotoxic neuronal death*. Autophagy, 2014. **10**(5): p. 846-60.
94. Koike, M., et al., *Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury*. Am J Pathol, 2008. **172**(2): p. 454-69.

95. Xing, S., et al., *Beclin 1 knockdown inhibits autophagic activation and prevents the secondary neurodegenerative damage in the ipsilateral thalamus following focal cerebral infarction*. *Autophagy*, 2012. **8**(1): p. 63-76.
96. Wen, Y.D., et al., *Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways*. *Autophagy*, 2008. **4**(6): p. 762-9.
97. Puyal, J., et al., *Postischemic treatment of neonatal cerebral ischemia should target autophagy*. *Ann Neurol*, 2009. **66**(3): p. 378-89.
98. Munoz-Pinedo, C. and S.J. Martin, *Autosis: a new addition to the cell death tower of babel*. *Cell Death Dis*, 2014. **5**: p. e1319.
99. Liu, Y. and B. Levine, *Autosis and autophagic cell death: the dark side of autophagy*. *Cell Death Differ*, 2015. **22**(3): p. 367-76.
100. Kang, C. and L. Avery, *To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation*. *Autophagy*, 2008. **4**(1): p. 82-4.
101. Li, I.H., et al., *Autophagy activation is involved in 3,4-methylenedioxymethamphetamine ('ecstasy')-induced neurotoxicity in cultured cortical neurons*. *PLoS One*, 2014. **9**(12): p. e116565.
102. Liang, J.H. and J.P. Jia, *Dysfunctional autophagy in Alzheimer's disease: pathogenic roles and therapeutic implications*. *Neurosci Bull*, 2014. **30**(2): p. 308-16.
103. Wu, X., et al., *Impaired autophagy contributes to adverse cardiac remodeling in acute myocardial infarction*. *PLoS One*, 2014. **9**(11): p. e112891.
104. Wu, F., et al., *Rotenone impairs autophagic flux and lysosomal functions in Parkinson's disease*. *Neuroscience*, 2015. **284**: p. 900-11.
105. Dehay, B., et al., *Pathogenic lysosomal depletion in Parkinson's disease*. *J Neurosci*, 2010. **30**(37): p. 12535-44.
106. Arduino, D.M., et al., *Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic*. *Hum Mol Genet*, 2012. **21**(21): p. 4680-702.
107. Lin, T.K., et al., *Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy*. *Int J Mol Sci*, 2014. **15**(1): p. 1625-46.
108. Harris, H. and D.C. Rubinsztein, *Control of autophagy as a therapy for neurodegenerative disease*. *Nat Rev Neurol*, 2012. **8**(2): p. 108-17.
109. Hollerhage, M., et al., *Trifluoperazine rescues human dopaminergic cells from wild-type alpha-synuclein-induced toxicity*. *Neurobiol Aging*, 2014. **35**(7): p. 1700-11.
110. Rose, C., et al., *Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease*. *Hum Mol Genet*, 2010. **19**(11): p. 2144-53.
111. Ravikumar, B., et al., *Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease*. *Nat Genet*, 2004. **36**(6): p. 585-95.
112. Majumder, S., et al., *Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits*. *PLoS One*, 2011. **6**(9): p. e25416.
113. Crews, L., et al., *Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy*. *PLoS One*, 2010. **5**(2): p. e9313.
114. Malagelada, C., et al., *Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease*. *J Neurosci*, 2010. **30**(3): p. 1166-75.
115. Buttner, S., et al., *Spermidine protects against alpha-synuclein neurotoxicity*. *Cell Cycle*, 2014. **13**(24): p. 3903-8.
116. Chu, C., et al., *Induction of autophagy by a novel small molecule improves abeta pathology and ameliorates cognitive deficits*. *PLoS One*, 2013. **8**(6): p. e65367.

117. Zhu, Z., et al., *Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance*. J Neurosci, 2013. **33**(32): p. 13138-49.
118. Yang, D.S., et al., *Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits*. Brain, 2011. **134**(Pt 1): p. 258-77.
119. Stein, V.M., et al., *Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C*. J Neuropathol Exp Neurol, 2012. **71**(5): p. 434-48.
120. Shen, W., et al., *Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons*. J Neurochem, 2014. **129**(5): p. 884-94.
121. Liao, G., et al., *Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brain*. Am J Pathol, 2007. **171**(3): p. 962-75.
122. Meske, V., et al., *How to reduce the accumulation of autophagic vacuoles in NPC1-deficient neurons: A comparison of two pharmacological strategies*. Neuropharmacology, 2014. **89c**: p. 282-289.
123. Sardiello, M., et al., *A gene network regulating lysosomal biogenesis and function*. Science, 2009. **325**(5939): p. 473-7.
124. Polito, V.A., et al., *Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB*. EMBO Mol Med, 2014. **6**(9): p. 1142-60.

FIGURE LEGENDS

Fig 1. The schematic diagram of autophagy process

The autophagy process includes autophagosome biogenesis, autophagosome-lysosome fusion and cargo degradation. The ULK1/2-Atg13-FIP2000 complex, negatively regulated by mTOR, senses the signals for autophagosome initiation. The class III PI3-kinase complex, containing Vps34, beclin-1/Atg6, p150/Vps15, and Atg14, generates PI3P required for autophagosome nucleation. Autophagosome elongation involves two ubiquitin-like (UBL) conjugations: the conjugation of the UBL protein Atg12 to Atg5, and the conjugation of the UBL protein LC3 to phosphatidylethanolamine (PE). Atg5-Atg12 conjugation is catalysed sequentially by E1-like enzyme Atg7 and E2-like enzyme Atg10. The Atg5-Atg12 complex then forms a larger complex with Atg16 and the site of Atg16 recruitment is enabled by its binding to WIPI2, which, in turn, is recruited to membranes enriched in PI3P or PI5P. The Atg5-12 conjugate (Atg5-12) is an E3 ligase that catalyses LC3-PE (LC3-II) conjugation that also requires E1-like Atg7 and E2-like Atg3. LC3-II, the lipidated form of LC3, is required for the expansion and completion of pre-autophagosomal membranes.

Fig 2. One hypothetical model where the extent of autophagy dictates the fate of neurons under stress

When faced with a harsh stress, neurons rely on autophagy induction as a means of protection and damage limitation, suppressing cell death and promoting survival. This means an inefficient or inhibited level of autophagy can be detrimental for neuron health. On the other end of the spectrum, an excessive autophagic response may result in degradation of vital cellular components, culminating in autophagic cell death (ACD). Therefore, it seems in order for autophagy to exert its protective effects, a balance needs to be maintained to avoid neuron death.

Fig 3. Dysfunctional lysosomal clearance of autophagy promotes the accumulation of toxic aggregates associated with neurodegeneration

Efficient autophagic clearance is required to remove potentially toxic aggregate-prone proteins in neurons. In instances of lysosomal dysfunction, these accumulations can form, and, coupled with the loss of protective autophagy, generate further damage to neurons. Ultimately, these stresses can equate to neuron loss and neurodegeneration. Strategies of restoring lysosome integrity and function allow autophagy degradation to resume, and may provide a means of prevention against these pathologies occurring.

Table 1: Selected strategies of autophagy flux restoration in neurodegenerative models (mammalian where available)

Strategy	Neurodegenerative Disease	Changes to Pathology	Reference
Pharmacological Rapamycin	Alzheimer's Disease	Autophagy induction; reductions in A β and cognitive recovery in AD mice	[71],[112]
	Huntington's Disease	Reductions in Htt aggregate formation, improvements in behavioural tests in mice	[113],[114]
	Parkinson's Disease	Reductions in α -synuclein accumulations, alleviations to neurodegenerative behaviour in mice	[111]
Rilmenidine	Huntington's Disease	Autophagy induction; enhanced clearance of mutant Htt, improved motor performance in mice	[110]
Spermidine	Parkinson's Disease	Autophagy induction; Improved motor performance in fruit fly, Reduced dopaminergic neuron loss in nematodes	[115]
Arctigenin	Alzheimer's Disease	Autophagy induction; Reduction in A β plaques through inhibition of formation and enhanced clearance, improved memory in mice	[117]
GTM-1	Alzheimer's Disease	Autophagy induction and increased flux; Removal of A β oligomers, cognitive improvements in mice	[116]
Glucosylceramide inhibitors	Niemann-Pick Type-C 1	Corrections to autophagy flux; Improved clearance of cholesterol and autophagic vesicles in mouse and feline models, prolonged neuron survival	[119],[120]
Genetic TFEB	Alzheimer's Disease Huntington's Disease Parkinson's Disease	Upregulation of lysosomal and autophagy genes; Enhanced clearance of Tau, α -synuclein and mutant Htt aggregates	[124] [25] [67]

Fig 1




Fig 2




Fig 3

